Apellis Pharmaceuticals, Inc.
Biopharmaceutical company developing therapies by targeting the complement cascade.
APLS | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 100 FIFTH AVENUE, 2451 WALTHAM
- Website:
- https://apellis.com/
- Sector:
- Manufacturing
Description
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Apellis Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Apellis Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Apellis Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
